Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Response criteria for phase II studies of supratentorial malignant glioma.

1990 • 2,401 citations

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

2001 • 981 citations

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

2004 • 958 citations

Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin

1997 • 953 citations

4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway

1998 • 872 citations

Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer

1993 • 777 citations

PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme

2001 • 609 citations

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

2000 • 587 citations

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten^+/−mice

2001 • 574 citations

Somatic mutations of PTEN in glioblastoma multiforme.

1997 • 526 citations

Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway

1998 • 510 citations

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

2004 • 504 citations

Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.

1997 • 443 citations

The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas

2004 • 368 citations

Chemotherapy for malignant gliomas

1988 • 343 citations

Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate Cancer

2004 • 324 citations

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

2002 • 318 citations

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

2001 • 229 citations

Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin

2002 • 216 citations

Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis

1992 • 201 citations

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

2002 • 200 citations

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

2003 • 178 citations

Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.

1996 • 170 citations

Opposite Translational Control of GLUT1 and GLUT4 Glucose Transporter mRNAs in Response to Insulin

1999 • 152 citations

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

2003 • 117 citations

Temozolomide in the treatment of recurrent malignant glioma

2004 • 88 citations

Chemotherapy for high-grade gliomas

2000 • 79 citations

The Role of Chemotherapy in Recurrent Malignant Gliomas: An Overview

1996 • 70 citations

Response and progression in recurrent malignant glioma

1999 • 53 citations

Recurrent malignant glioma in adults

2002 • 51 citations

Thallium-201 Single-Photon Emission Computed Tomography As an Early Predictor of Outcome in Recurrent Glioma

2003 • 46 citations

Mechanism of action of rapamycin (Sirolimus, Rapamune).

1996 • 40 citations

Response and progression in recurrent malignant glioma

1999 • 39 citations